<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987450</url>
  </required_header>
  <id_info>
    <org_study_id>RNN/267/17/KE</org_study_id>
    <nct_id>NCT04987450</nct_id>
  </id_info>
  <brief_title>Effect of Glucocorticoids on Inflammation and Bone Metabolism in Patients With Glomerular Disease</brief_title>
  <official_title>Effect of High-dose Glucocorticoids on Markers of Inflammation and Bone Metabolism in Patients With Primary Glomerular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lodz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the influence of high doses of intravenous corticosteroids&#xD;
      on plasma inflammation and bone markers in patients with primary glomerular disease. The&#xD;
      study would include 40 patients with chronic kidney disease. The main inclusion criterion is&#xD;
      clinical and histopathological diagnosis of primary glomerular disease and urine protein&#xD;
      excretion &gt;2.0 g/24h. The exclusion criteria include secondary glomerular disease, acute&#xD;
      kidney injury, acute or chronic inflammation, history of non-compliance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucocorticoids are one of the most widely used classes of drugs to treat inflammatory and&#xD;
      autoimmune diseases. They increase formation of osteoclasts and enhance bone resorption&#xD;
      thereby increasing risk of bone fractures and osteoporosis.&#xD;
&#xD;
      Sirtuin-1(SIRT-1) belongs to family of proteins involved in protection against inflammation&#xD;
      and oxidative stress. A role of SIRT-1 in regulation of bone metabolism during high-dose&#xD;
      steroid therapy is unknown.&#xD;
&#xD;
      The study protocol was approved by the local Bioethics Committee and the study is conducted&#xD;
      according to the Declaration of Helsinki. Adult patients with the previous diagnosed primary&#xD;
      glomerular disease based on both clinical and renal biopsy findings are included.&#xD;
&#xD;
      Plasma concentration of SIRT-1, interleukin-6 (IL-6), fibroblast growth factor 23 (FGF-23),&#xD;
      sclerostin, calcium, phosphate, parathormone (PTH) and urine excretion of total protein,&#xD;
      albumin, creatinine, calcium and phosphate are measured at baseline. Then the patients&#xD;
      receive three intravenous pulses of methylprednisolone of 500 mg followed by oral prednisone&#xD;
      0.8-1.0 mg/kg/24h. The same measurements are repeated 4, 7 and 30 days after starting the&#xD;
      steroid treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the change of plasma SIRT-1 level after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of plasma sclerostin level after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of plasma FGF-23 level after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of plasma IL-6 level after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of plasma total calcium level after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of plasma phosphate level after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of plasma PTH level after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of urine albumin/creatinine ratio after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of urine total protein/creatinine ratio after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of urine phosphate/creatinine ratio after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of urine calcium/creatinine ratio after glucocorticoids administration</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glomerular Disease</condition>
  <arm_group>
    <arm_group_label>Study population</arm_group_label>
    <description>Plasma levels of SIRT-1, IL-6, FGF-23, sclerostin, calcium, phosphate, PTH and urine excretion of total protein, albumin, creatinine, calcium and phosphate are measured at baseline. Then the patients receive three intravenous daily pulses of methylprednisolone of 500 mg followed by oral prednisone 0.8-1.0 mg/kg/24h. The same measurements are repeated 4, 7 and 30 days after starting the steroid treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone, prednisone</intervention_name>
    <description>The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.</description>
    <arm_group_label>Study population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with primary glomerular disease who are diagnosed and hospitalized in&#xD;
        Nephrology Department in Łódź.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  previous diagnosed primary glomerular disease based on both clinical and renal biopsy&#xD;
             findings&#xD;
&#xD;
          -  an estimated glomerular filtration rate ≥15 ml/min/1.73m2&#xD;
&#xD;
          -  proteinuria ≥2.0 g/24h&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary glomerular disease&#xD;
&#xD;
          -  acute kidney injury&#xD;
&#xD;
          -  acute or chronic inflammation&#xD;
&#xD;
          -  malignancy&#xD;
&#xD;
          -  uncontrolled hypertension with systolic blood pressure higher than 160 mmHg&#xD;
&#xD;
          -  symptomatic hypotension&#xD;
&#xD;
          -  advanced heart failure&#xD;
&#xD;
          -  history of non-compliance, dementia or depression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michał Nowicki, Prof. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Hypertension and Kidney Transplantation Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michał Nowicki, Prof. MD.</last_name>
    <phone>+ 48 42 2014400</phone>
    <email>nefro@wp.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katarzyna Pęczek, Dr</last_name>
    <email>katarzyna.peczek90@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Lodz, Poland</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ireneusz Staroń, Study Chair</last_name>
      <email>ireneusz.staron@umed.lodz.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lodz</investigator_affiliation>
    <investigator_full_name>Michal Nowicki</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>glucocorticoids</keyword>
  <keyword>primary glomerular disease</keyword>
  <keyword>sirtuin-1</keyword>
  <keyword>sclerostin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

